45.81 USD
↘ 0.37 (0.80%)AT CLOSE (11:59 AM EDT)
Travere Therapeutics, Inc. Common Stock
TVTXNASDAQ • USD
47.20
↗ 1.39 (3.03%)
POST MARKET (AS OF 07:54 PM EDT)
Post Market
AS OF 07:54 PM EDT
47.20
↗ 1.39 (3.03%)
Market: CLOSED
Open?$46.50
High?$47.77
Low?$45.30
Prev. Close?$46.18
Volume?2.9M
Avg. Volume?2.3M
VWAP?$46.68
Rel. Volume?1.28x
Bid / Ask
Bid?$39.15 × 100
Ask?$52.32 × 100
Spread?$13.17
Midpoint?$45.74
Valuation & Ratios
Market Cap?4.3B
Shares Out?93.0M
Float?90.4M
Float %?98.0%
P/E Ratio?N/A
P/B Ratio?43.15
EPS?-$0.23
Dividend?0.00%
Ex-Dividend?N/A
Travere Therapeutics, Inc. Common Stock (TVTX) trades at $45.81 per share. Technicals currently rate "Buy" while our fundamental analysis reads "Neutral". This is driven by a robust Altman Z-Score, negative Return on Equity, a bullish Golden Cross on the moving averages and bullish moving average alignment. On the valuation front, TVTX trades at elevated multiples relative to its peers, earning a "Richly Valued" assessment.
Technical & fundamental data as of Jun 5, 2026.
News
Profile
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body.
Themes
Address
3611 VALLEY CENTRE DR
SAN DIEGO, CA 92130
Phone: 888-969-7879
SAN DIEGO, CA 92130
Phone: 888-969-7879
Technical OutlookBuy
Strong SellNeutralStrong Buy
Long-Term (Tide)?▲ Bullish(+2/3)
Medium-Term (Wave)?– Neutral(0/3)
Short-Term (Ripple)?▲ Bullish(+2/3)
MA Alignment?Golden Alignment
Full Technical Analysis →Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?40
Z-Score?71
Momentum?57
Short Sent.?51
Piotroski F-Score?4/9Mixed
Altman Z-Score?3.00Safe
Confidence?74%Moderate
Short InterestHigh
Short % of Float?15.50%High
Short Interest?14.0M
Days to Cover?4.5
Free Float90.4M
Avg Daily Volume3.1M
Settlement Date2026-05-15
Financial Health
Current Ratio?3.13Strong
Quick Ratio?3.08Strong
Cash Ratio?0.62Adequate
Debt/Equity?3.16High
ValuationRICHLY VALUEDvs 1 peers + S&P 500
Score33/100
P/E?N/A▾
P/B?43.15HIGH▾
Peers100
S&P3
P/S?7.94HIGH▾
Peers100
S&P13
P/FCF?108.6PRICEY▾
Peers100
S&P3
EV/EBITDA?279.3HIGH▾
Peers100
S&P3
EV/Sales?8.38HIGH▾
Peers100
S&P16
Returns & Efficiency
ROE?-21.7%WEAK▾
S&P7
ROA?-3.9%WEAK▾
S&P3
Cash Flow & Enterprise
FCF?$39.2M
Enterprise Value?$4.5B
Fundamentals ratios updated end of day